

Clinical Trial Protocol

Iranian Registry of Clinical Trials

17 Sep 2026

Open safety and efficacy trial of topical nano-liposomal form of Amphotericin B in comparison with national standard treatment for the treatment of cutaneous leishmaniasis caused by Leishmania major (Phase 3)

Protocol summary

Summary

1) Objectives -To evaluate the efficacy and safety of heat therapy plus topical nano-liposomal form of Amphotericin B compared with heat therapy plus placebo for the treatment of zoonotic cutaneous leishmaniasis (ZCL) caused by Leishmania major. -To evaluate the efficacy and safety of heat therapy for the treatment of zoonotic cutaneous leishmaniasis (ZCL) caused by Leishmania major (2)Design A randomized double blind comparative, efficacy and safety study. (3)setting and conduct Male and female volunteers aged 12-60 years, with ZCL caused by Leishmania major from an endemic area of ZCL in Iran will be recruited. ZCL diagnosis will be based on parasitologically proven cases of cutaneous leishmaniasis (CL) and the species will be confirmed by PCR. (4)Participants including major eligibility criteria Inclusion:Males & females 12-60 years of age. Parasitological proven CL caused by L. major (identification is done by using PCR). Exclusion:Pregnant or lactating women, Concurrent or chronic illness based on previous history, Duration of lesion more than 3 months, Number of lesions more than 5,Ulcer size greater than 3 cm in their largest diameter. (5)Intervention A)Heat therapy machine using current field radio frequency generator (ThermoMed™ 1.8TM, 140 Thermosurgery Technologies Inc., Phoenix, USA) already was donated by WHO to PI for another study. B)Topical nano-liposomal Amphotericin B 0.4% (SinaAmpholeish): (6)Outcomes Primary outcome:Complete cure, defined as complete reepithelization of the lesion and loss of induration. Secondary outcome:Partial cure, More than 50% reduction in size or induration compared tBatch baseline.

General information

Acronym

IRCT registration information

IRCT registration number: **IRCT201612101475N11**

Registration date: **2017-02-17, 1395/11/29**

Registration timing: **registered_while_recruiting**

Last update:

Update count: **0**

Registration date

2017-02-17, 1395/11/29

Registrant information

Name

Ali Khamesipour

Name of organization / entity

Center for Research and Training in Skin Diseases and Leprosy, Tehran University of Medical Sciences

Country

Iran (Islamic Republic of)

Phone

+98 21 8897 0657

Email address

khamesipour@tums.ac.ir

Recruitment status

Recruitment complete

Funding source

Center for Research and Training in Skin Diseases and Leprosy, Tehran University of Medical Sciences

Expected recruitment start date

2016-12-15, 1395/09/25

Expected recruitment end date

2017-12-15, 1396/09/24

Actual recruitment start date

empty

Actual recruitment end date

empty

Trial completion date

empty

Scientific title

Open safety and efficacy trial of topical nano-liposomal form of Amphotericin B in comparison with national standard treatment for the treatment of cutaneous leishmaniasis caused by Leishmania major (Phase 3)

Public title

safety and efficacy comparison trial of topical nano-liposomal form of Amphotericin B with national standard treatment for cutaneous leishmaniasis caused by Leishmania major (Phase 3)

Purpose

Treatment

Inclusion/Exclusion criteria

Inclusion criteria: Males & females 12-60 years of age;Parasitologically proven CL caused by L. major (identification is done by using PCR); Otherwise healthy subjects on the basis of medical history; physical examination and results of blood test if requested by the physician; Ability to understand the principles of the trial and Signing an informed consent voluntarily and knowingly. Exclusion Criteria: Pregnant or lactating women; Concurrent or chronic illness based on previous history;Duration of lesion more than 3 months;Number of lesions more than 5;Ulcer size greater than 3 cm in their largest diameter; History of full course of standard treatment (antimonials); Involvement in any other drug or vaccine trial during the study period.

AgeFrom **12 years** old to **60 years** old**Gender**

Both

Phase

3

Groups that have been masked*No information***Sample size**Target sample size: **150****Randomization (investigator's opinion)**

Randomized

Randomization description**Blinding (investigator's opinion)**

Double blinded

Blinding description**Placebo**

Used

Assignment

Parallel

Other design features

Cohort Study

Secondary Ids

empty

Ethics committees**1****Ethics committee****Name of ethics committee**

Isfahan University of Medical Sciences Ethical Committee

Street address

Skin Diseases and Leishmaniasis Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.Khoram St,Jomhuri Sq,Postal Code:81876-98191.Isfahan,Iran.

City

Isfahan

Postal code

81876-98191

Approval date

2016-11-09, 1395/08/19

Ethics committee reference number

495058

Health conditions studied**1****Description of health condition studied**

Cutaneous Leishmaniasis

ICD-10 code

B55.1

ICD-10 code description

Cutaneous leishmaniasis

Primary outcomes**1****Description**

reepithelization of the lesions/Complete cure

Timepoint

Monthly

Method of measurement

lesion measurement/Digital photos

Secondary outcomes**1****Description**

partial cure : Decrease size of the lesions

Timepoint

Monthly

Method of measurement

lesion measurement /Digital photos

Intervention groups**1****Description**

Topical nano-liposomal Amphotericin B 0.4%

(SinaAmpholeish) twice a day for 28 days

Category

Treatment - Drugs

2

Description

Standard treatment of weekly injections of meglumine antimonite (Glucantime) plus or without biweekly cryotherapy until cure of the lesion.

Category

Treatment - Drugs

3

Description

Placebo Gel without liposomes or Amphotericin B

Category

Treatment - Drugs

Recruitment centers

1

Recruitment center

Name of recruitment center

Skin Diseases and Leishmaniasis Research Center,
Isfahan University of Medical Sciences,

Full name of responsible person

Street address

City

Isfahan

Sponsors / Funding sources

1

Sponsor

Name of organization / entity

National Institute for Medical Research Development
(NIMAD)

Full name of responsible person

Dr. Ghaffari

Street address

No.21, Besat St., Fatemi Av., Tehran, Iran.

City

Tehran

Grant name

Grant code / Reference number

Is the source of funding the same sponsor organization/entity?

Yes

Title of funding source

National Institute for Medical Research Development
(NIMAD)

Proportion provided by this source

Public or private sector

empty

Domestic or foreign origin

empty

Category of foreign source of funding

empty

Country of origin

Type of organization providing the funding

empty

2

Sponsor

Name of organization / entity

Center for Research and Training in Skin Diseases and
Leprosy, TUMS

Full name of responsible person

Prof. Ali Khamesipour

Street address

No. 415, Taleghani St., Tehran Iran

City

Tehran

Grant name

Grant code / Reference number

Is the source of funding the same sponsor organization/entity?

Yes

Title of funding source

Center for Research and Training in Skin Diseases and
Leprosy, TUMS

Proportion provided by this source

Public or private sector

empty

Domestic or foreign origin

empty

Category of foreign source of funding

empty

Country of origin

Type of organization providing the funding

empty

3

Sponsor

Name of organization / entity

Skin Diseases and Leishmaniasis Research Center
(SDLRC), Isfahan University of Medical Sciences

Full name of responsible person

Dr.Fatemeh Sokhanvari MD

Street address

Khoram St.,Jomhouri Sq.,Isfahan,Iran.

City

Isfahan

Grant name

Grant code / Reference number

Is the source of funding the same sponsor organization/entity?

Yes

Title of funding source

Skin Diseases and Leishmaniasis Research Center
(SDLRC), Isfahan University of Medical Sciences

Proportion provided by this source

Public or private sector

empty

Domestic or foreign origin

empty

Category of foreign source of funding

empty

Country of origin

Type of organization providing the funding
empty

4

Sponsor

Name of organization / entity

Exir Nano Sina CO.

Full name of responsible person

Dr.Jafaari, MahmoudReza

Street address

Unit 7, No.94, FathiShaghaghi St, Jahanmehr St,
Gomnam Ave, Fatemi Sq.,

City

Tehran

Grant name

Grant code / Reference number

Is the source of funding the same sponsor organization/entity?

Yes

Title of funding source

Exir Nano Sina CO.

Proportion provided by this source

Public or private sector

empty

Domestic or foreign origin

empty

Category of foreign source of funding

empty

Country of origin

Type of organization providing the funding

empty

Person responsible for general inquiries

Contact

Name of organization / entity

Skin Disease and Leishmaniasis Research Center,
Isfahan University of Medical Sciences

Full name of responsible person

Dr.Fatemeh Sokhanvari MD

Position

Doctor

Other areas of specialty/work

Street address

Isfahan University of Medical Sciences, Khoram St,
Jomhuri Sq, Isfahan, Iran.

City

Isfahan

Postal code

Phone

+98 31 3337 3736

Fax

Email

dr_f_sokhanvari@yahoo.com

Web page address

Person responsible for scientific inquiries

Contact

Name of organization / entity

Center for Research and Training in Skin Diseases and
Leprosy, Tehran University of Medical Science

Full name of responsible person

Prof. Ali Khamesipour

Position

Prof./PhD

Other areas of specialty/work

Street address

No.415 Taleghani St, Tehran, Iran.

City

Tehran

Postal code

Phone

+98 21 8897 0658

Fax

Email

ali.khamesipour@gmail.com

Web page address

Person responsible for updating data

Contact

Name of organization / entity

Center for Research and Training in Skin Diseases and
Leprosy, Tehran University of Medical Science

Full name of responsible person

Prof. Ali Khamesipour

Position

Prof/PhD

Other areas of specialty/work

Street address

No. 415, Taleghani St., Tehran, Iran.

City

Tehran

Postal code

Phone

+98 21 8897 0657

Fax

+98 88970658

Email

khamesipour_ali@yahoo.com

Web page address

Sharing plan

Deidentified Individual Participant Data Set (IPD)

empty

Study Protocol

empty

Statistical Analysis Plan

empty

Informed Consent Form

empty

Clinical Study Report

empty

Analytic Code

empty

Data Dictionary

empty